This pharmaceutical company has another drug review! Since the second half of the year, a total of 3 varieties have been evaluated

【Pharmaceutical Network Enterprise News】On November 25, Guangzhou Baiyunshan Pharmaceutical Group Co.
, Ltd.
issued an announcement
that the wholly-owned subsidiary drugs passed the consistency evaluation of generic drugs.
According to the announcement, isoniazid tablets (specifications: 300mg, 100mg) of Mingxing Pharmaceutical, a wholly-owned subsidiary of the company, have passed the consistency evaluation
of the quality and efficacy of generic drugs.
Isoniazid tablets are anti-tuberculosis drugs
suitable for the treatment of all types of tuberculosis, including tuberculous meningitis and other mycobacterial infections.
According to data from Minai.
com, in 2021, the sales of isoniazid tablets in China's public hospitals and urban retail pharmacies were RMB 19.
52 million and RMB 6.
91 million respectively
.
At present, in addition to Mingxing Pharmaceutical, the manufacturers of isoniazid tablets listed in China include Shenyang Hongqi Pharmaceutical Co.
, Ltd.
, Hangzhou Minsheng Pharmaceutical Co.
, Ltd.
, Guangdong South China Pharmaceutical Group Co.
, Ltd.
, Huazhong Pharmaceutical Co.
, Ltd.
, etc
.
For pharmaceutical companies, the consistency evaluation of generic drugs is generally conducive to enhancing the market competitiveness of the drug, and the pharmaceutical company means that it has obtained the "admission ticket"
to participate in centralized procurement.
It is reported that Guangzhou Baiyunshan actively promotes the consistency evaluation of generic drugs, and since the second half of the year, the company has issued three evaluation announcements, with a total of 3 varieties being evaluated
.
On July 27, Guangzhou Baiyunshan announced that its subsidiary Tianxin Pharmaceutical, candesartan cilexetil tablets (specification: 4mg) have passed the quality and efficacy consistency evaluation
of generic drugs.
This product is indicated for essential hypertension
.
At present, domestic manufacturers of candesartan cilexetil tablets also include Chongqing Shenghuaxi Pharmaceutical, Hunan Tiandi Hengyi Pharmaceutical, etc
.
According to data from Minai.
com, in 2021, the sales of candesartan cilexetil tablets in Chinese cities, county-level public hospitals and urban retail pharmacies were RMB 226 million and RMB 173 million
, respectively.
On July 15, Guangzhou Baiyunshan issued an announcement that the cefaladine capsules (0.
125g, 0.
25g) of Baiyunshan Pharmaceutical General Factory, a subsidiary of the company, have passed the consistency evaluation
of the quality and efficacy of generic drugs.
Cefaladine is a generation of cephalosporin antibiotics, suitable for acute pharyngitis, tonsillitis, otitis media, bronchitis and pneumonia and other respiratory infections, genitourinary tract infections and skin and soft tissue infections caused by sensitive bacteria
.
At present, domestic manufacturers of cefaladine capsules also include Sino-US Shanghai Squibb, Xinhua Pharmaceutical, Shiyi Ouyi and so on
.
According to data from Minai.
com, in 2021, the sales of cefaladine capsules in Chinese cities, county-level public hospitals and urban retail pharmacies were RMB 25.
72 million and RMB 86.
04 million respectively
.
The smooth progress of the evaluation work is often inseparable from the company's continuous R&D investment
.
According to the third quarterly report of Baiyunshan, the company's research and development expenses in the first three quarters of this year were 1.
584 billion yuan, an increase of more than 100 million yuan from 1.
469 billion yuan
in the same period of the previous year.
It is understood that Guangzhou Baiyunshan has been focusing on the pharmaceutical and health industry, and after years of careful construction and accelerated development, it has basically realized the layout of the whole industrial chain of the biomedical health industry, forming four major business sectors
of Great Southern Medicine, Great Health, Great Commerce and Great Medical.
In the third quarter of 2022, the company achieved operating income of 54.
806 billion yuan, a year-on-year increase of 2.
37%; Net profit attributable to shareholders of the Company was RMB3,474 million, up 4.
91%
year-on-year.
In terms of market performance, as of the close on November 25, 2022, Baiyunshan closed at 28.
88 yuan, down slightly by 0.
1%, with a turnover rate of 0.
62%, a volume of 87,700 lots and a turnover of 251 million yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.